Neurotrophic Keratopathy Treatment Market Poised for Robust 15% CAGR Growth by 2032 with Emerging Pipeline Therapies Seeking to Displace Current Standard of Care
-
Neurotrophic keratopathy market size in the 7MM was $182 million in 2022 and is projected to grow at a CAGR of 15.4% by 2032.
-
Total neurotrophic keratopathy prevalent cases in the 7MM were approx 138K in 2022.
-
Leading companies like ReGenTree, RegeneRx, Oyster Point Pharma, etc. are developing novel therapies.
-
Promising pipeline therapies include RGN-259, OC-01, REC 0559, CSB-001, BRM424.
-
Approved drug Oxervate is expensive and has side effects, presenting an opportunity for emerging therapies.